Using gamma stimulation to improve motor function in Parkinson's disease
Targeting the Motor Cortex in Parkinson's Disease by Gamma-transcranial Alternating Current Stimulation: Pathophysiological and Therapeutic Implications
This study is testing if a new brain stimulation technique can help improve movement and learning in people with Parkinson's disease.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 84 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Neuromed IRCCS Academic / other |
| Locations | 1 site (Pozzilli) |
| Trial ID | NCT06297538 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of gamma transcranial alternating current stimulation (tACS) on patients with Parkinson's disease, focusing on its potential to enhance motor performance and learning. By targeting the primary motor cortex, the study aims to restore gamma oscillations that are typically reduced in Parkinson's patients, which may improve motor control and plasticity. Participants will receive either active tACS or a sham treatment to assess the clinical effects of this non-invasive neurophysiological intervention.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals diagnosed with Parkinson's disease who do not have severe cognitive or psychiatric comorbidities.
Not a fit: Patients with advanced Parkinson's disease (H&Y>3), severe cognitive impairments, or those with specific neuropsychiatric disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved motor function and learning abilities in patients with Parkinson's disease.
How similar studies have performed: While the use of tACS is a relatively novel approach, preliminary studies in related areas suggest potential benefits, though this specific application in Parkinson's disease is less explored.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * PD diagnosis Exclusion Criteria: * severe cognitive and psychiatric comorbidities * H\&Y\>3 * levodopa-induced dyskinesia and tremor-dominant phenotype * history of additional neuropsychiatric disorders * intake of medications acting on brain excitability or plasticity * contraindications to non-invasive brain stimulation
Where this trial is running
Pozzilli
- IRCCS Neuromed — Pozzilli, Italy (Recruiting)
Study contacts
- Study coordinator: Giulia Paparella
- Email: giulia.paparella@uniroma1.it
- Phone: 3384780752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.